BC
BIO icon

Bridgefront Capital’s Bio-Rad Laboratories Class A BIO Stock Holding History

Bridgefront Capital’s Portfolio BIO Stock Details BIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-1,456
Closed -$406K – 527
2026
Q1 		$406K Buy
+1,456
New +$419K 0.1% 315
2025
Q3 		– Sell
-971
Closed -$234K – 596
2025
Q2 		$234K Sell
971
-478
-33% -$113K 0.06% 507
2025
Q1 		$353K Buy
+1,449
New +$436K 0.1% 346

Other funds holding BIO

First Eagle Investment Management
First Eagle Investment Management New York $60.8B AUM 26.63% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AI
Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
EARNEST Partners
EARNEST Partners Atlanta, Georgia $27.7B AUM 52.44% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Bridgefront Capital's BIO Position: Q2 2026 in Review

Bridgefront Capital sold out of Bio-Rad Laboratories Class A (BIO) in Q2 2026, closing a stake of 1,456 shares — an estimated $406K sold.

Bridgefront Capital first reported a position in BIO in Q1 2025 and held it in 3 quarters. The position peaked at $406K in Q1 2026. 397 funds tracked by Wall St. Rank hold BIO as of Q2 2026.

  • Bridgefront Capital reported no remaining Bio-Rad Laboratories Class A position as of Q2 2026 after selling out during the quarter.
  • Bridgefront Capital sold 1,456 Bio-Rad Laboratories Class A shares in Q2 2026, an estimated $406K.
  • Bridgefront Capital first reported a position in Bio-Rad Laboratories Class A in Q1 2025 and held it in 3 quarters.
  • Bridgefront Capital's Bio-Rad Laboratories Class A position peaked at $406K in Q1 2026.
  • 397 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q2 2026.

Based on Bridgefront Capital's 13F filing for Q2 2026, filed 14 Aug 2026.